沉默信息调节因子1与乳腺癌临床病理指标的相关性及生存分析

Correlation and survival analysis of SIRT1 expression level and clinicopathological features of breast cancer patients

目的探讨沉默信息调节因子1(SIRT1)在乳腺癌及癌旁组织中的表达及与其他临床病理指标的相关性,并分析其与术后生存数据的关系。方法检测120例乳腺癌组织及53例癌旁组织中SIRT1的表达情况,比较两组表达率的差异,以及乳腺癌组SIRT1表达水平与其他临床病理指标的相关性。结果乳腺癌组的阳性表达率高于癌旁组织组,差异有统计学意义(53.3%vs 34.0%,χ2=5.533,P=0.02)。临床病理指标分析显示,SIRT1表达水平与肿瘤大小及Ki-67表达情况呈密切相关性(χ2=6.790、21.316,P=0.009、0.000),与年龄、淋巴结转移、临床分期、组织学分级、雌激素受体(ER)、孕雌激素受体(PR)、Her-2表达差异无统计学意义。生存分析显示,SIRT1蛋白表达水平高的乳腺癌患者预后较表达水平低的患者差,差异有统计学意义(χ2=9.320,P<0.05)。结论 SIRT1在乳腺癌组织中的表达较癌旁组织明显升高,随着肿瘤的增大而表达增强,且与肿瘤增殖指标Ki-67正相关,其高表达的患者预后较差,提示其可能在乳腺癌的发生发展中起着正向促进作用,高表达预示着乳腺癌细胞增殖较快,预后不佳。

Objective To detect the expression of silent information regulator 1(SIRT1) in breast cancer and adjacent paracancerous tissues, and to analyze the correlation between its expression level and other clinical features of breast cancer and its significance in prognosis. Methods The expression of SIRT1 was detected by immunohistochemistry in 120 breast cancer tissues and 53 adjacent paracancerous tissues. The difference between the two groups and the relationship between SIRT1 expression and other clinical features were tested by chi-square test. Survival analysis was calculated by Kaplan-Meier method,and the survival rate was compared by Log-rank test. Results The expression of SIRT1 in breast cancer group was significantly higher than adjacent paracancerous tissues group(53.3% vs 34.0%, χ2=5.533, P=0.02). SIRT1 expression level showed positive correlation with tumor size and expresion of Ki- 67(χ2=6.790, 21.316, P=0.009, 0.000), but no statistical correlation with lymph node metastasis, clinical stage,histological grade, ER, PR and Her- 2 expression. Statistical analysis showed that compared with low SIRT1 expression, patients with high SIRT1 expression level had significantly poorer prognosis(χ2=9.320,P<0.05). Conclusions The expression of SIRT1 is obviously increased in breast cancer patients thanthat in adjacent paracancerous tissues, and its expression is correlated with tumor size and expression of Ki-67. These results may implicate that SIRT1 will improve the development of breast cancer and the higher expression of SIRT1 indicates the activated proliferation and poor survival rate.